Omaxe Subsidiary Secures RERA Approval; Shares Rise 6.33%

Mumbai, April 23: Omaxe Limited subsidiary has received regulatory approval for a commercial development in Lucknow.

The company said in an exchange filing that Omaxe Garv Buildtech Private Limited has secured RERA registration for its “Commercial-3 Block-3” project in Sarojini Nagar. This approval from the Uttar Pradesh Real Estate Regulatory Authority allows the company to formally move ahead with marketing and sales.

With registration in place, the company can begin engaging buyers, opening bookings and building a sales pipeline.

Stock Market Snapshot

Omaxe share price reacted positively to the update on April 23, 2026, reflecting improved visibility on the project’s next phase.

The stock traded at ₹88.36, up 6.33% as of 12:22 IST, compared with the previous close of ₹83.10. The gains came through steadily during the session, rather than all at once, indicating sustained interest from market participants.

For investors, approvals like this often signal that a project is moving closer to generating revenue, even if the actual cash flows take time to materialise.

Why This Step Matters

A RERA registration ensures the project meets disclosure and compliance standards. It also brings a level of accountability around timelines and execution, which tends to build trust with buyers.

The approval is valid until December 17, 2030, giving the company a defined window to execute and complete the project.

Company Background

Omaxe Limited operates across residential and commercial real estate, with projects spread across multiple cities.

Its developments typically move in phases, depending on approvals, demand conditions and execution timelines. Over the years, the company has built a portfolio that includes townships, commercial spaces and mid-income housing.

Like most real estate players, its performance is closely tied to how efficiently it moves projects from approval to execution.

Conclusion

While the share price has moved up on the news, the longer-term impact will depend on how quickly Omaxe can translate this approval into sales and on-ground progress.

Source:

• https://www.nseindia.com/get-quote/equity/OMAXE/Omaxe-Limited
• https://nsearchives.nseindia.com/corporate/OMAXE_23042026114518_Intimation_RERA_23042026_sd.pdf